EyePoint (STU:PV3B) Other Current Payables: €0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:PV3B EyePoint Inc STU:PV3B
41 GF Score
Price €10.70
GF Value €0.64
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is EyePoint Other Current Payables?

EyePoint STU:PV3B -1.83% 41 Other Current Payables is €0.00 Mil as of Mar. 2026. GuruFocus rates STU:PV3B with a GF Score™ of 41/100 and a GF Value™ of €0.64 (Significantly Overvalued). The stock has 7 warning signs investors should review.

EyePoint's Other Current Payables for the quarter that ended in Mar. 2026 was €0.00 Mil.

EyePoint Other Current Payables Related Terms

EyePoint Other Current Payables Historical Data

* Premium members only.

The historical data trend for EyePoint's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

EyePoint Other Current Payables Chart

EyePoint Annual Data
Trend Jun16 Jun17 Jun18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

EyePoint Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:PV3B
41GF Score
EyePoint Inc STU:PV3B
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

EyePoint Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of €0.00 Mil mean?
EyePoint (STU:PV3B) has a Other Current Payables of €0.00 Mil as of Mar. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on EyePoint and its competitors.
Is EyePoint's Other Current Payables too high?
EyePoint's current Other Current Payables is €0.00 Mil. Overall, EyePoint has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does EyePoint's Other Current Payables compare to SPTX and CRVS?
EyePoint's Other Current Payables of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on EyePoint and its competitors. EyePoint's current Other Current Payables is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EyePoint stock overvalued right now?
Based on GuruFocus' analysis, EyePoint (STU:PV3B) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.64, compared to a current price of €10.70 — trading 1571.9% above its estimated fair value. The current Other Current Payables is €0.00 Mil. EyePoint's overall GF Score™ is 41/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For EyePoint (STU:PV3B), the current Other Current Payables is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is EyePoint (STU:PV3B) Overvalued in 2026?

Based on GuruFocus' analysis, EyePoint stock appears to be overvalued. The current stock price of €10.70 is trading 1571.9% above its estimated GF Value™ of €0.64. GuruFocus considers EyePoint to be Significantly Overvalued.

Key valuation signals for STU:PV3B:

  • Other Current Payables: €0.00 Mil
  • GF Value™: €0.64 vs. price of €10.70 (1571.9% above fair value)
  • GF Score™: 41/100 with 7 warning signs

No single metric tells the full story. See the STU:PV3B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

EyePoint Business Description

Other Exchanges EYPT:USA
Address 480 Pleasant Street, Suite C-400, Watertown, MA, USA, 02472
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
41GF Score

Get the complete analysis for STU:PV3B

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€10.70
Price
€0.64
GF Value